Welcome to our dedicated page for ALRT news (Ticker: ALRT), a resource for investors and traders seeking the latest updates and insights on ALRT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALRT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALRT's position in the market.
ALR Technologies (ALRT) has signed a Memorandum of Understanding with Infinovo Medical Co. Ltd for a global supply agreement regarding the P3 Continuous Glucose Monitor (CGM) aimed at the animal health sector. The collaboration will integrate Infinovo’s CGM with ALRT’s GluCurve platform, with testing in veterinary clinics expected to begin by late December 2021 or early January 2022 and conclude by February 2022. ALRT plans to launch the GluCurve Pet CGM commercially as early as June 2022, enhancing diabetes management solutions for veterinarians.
ALR Technologies (ALRT) announces the upcoming launch of GluCurve™, the first continuous glucose monitor (CGM) designed for diabetic dogs and cats. This innovative system eliminates the need for traditional glucose curves, providing a pain-free and efficient method for monitoring blood glucose levels. Market research indicates a significant demand, with 97% of veterinarians expressing interest in adopting GluCurve™. The system offers automatic readings every 5 minutes for up to 14 days, aiming to redefine diabetic care for pets globally.
ALR Technologies (ALRT) has released a new investor presentation showcasing its strategic positioning in the diabetes management market. The company highlights recent leadership additions and is engaged in high-level negotiations that may positively impact its fundamentals. The newly designed corporate website aims to provide investors with insights into the company's innovations in human and animal diabetes care. ALRT offers a comprehensive diabetes management solution, including an FDA-cleared system and a predictive algorithm for treatment tracking. The company also plans to expand its services to other chronic diseases.
ALR Technologies SG Pte. Ltd. (OTCQB: ALRT) announced progress in partnership discussions regarding the GluCurve Pet CGM with two leading pharmaceutical companies in animal health. These discussions aim to select a strategic partner for investment in the product. The GluCurve Pet CGM offers a comprehensive solution for diabetes management in pets, streamlining glucose monitoring and improving care. CEO Sidney Chan thanked shareholders for their support during this process, emphasizing the potential benefits the collaboration could bring to pet owners and veterinarians.
ALR Technologies SG Pte. Ltd. (OTCQB: ALRT) has launched the GluCurve Pet CGM, the first continuous glucose monitor designed specifically for diabetic companion animals. This innovative device aims to streamline the diabetes management process for pets, replacing the traditional blood glucose curve method, which is often stressful and inefficient. The CGM will provide accurate readings every 5 minutes for up to 14 days, benefiting veterinarians and pet owners alike. Expected market availability is set for 2022, targeting the growing pet diabetes sector, which includes approximately 1 million insulin-dependent pets in the U.S.
ALR Technologies Inc. (OTC:QB - ALRT) has announced plans to redomicile to Singapore, aiming to strengthen its position in the global diabetes market. Shareholders will exchange their U.S. shares for those in a new Singapore entity on a one-for-one basis, pending regulatory approvals. CEO Sidney Chan emphasized that this move will enhance patient care across ASEAN countries and China, representing over 60% of the global diabetic population. The company also outlined strategic initiatives to engage with local communities and leverage traditional medicine for diabetes management.
FAQ
What is the market cap of ALRT (ALRT)?
